Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report
Indian Journal of Ophthalmology, 05/14/2012Sharma A et al.
The authors report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained–release intravitreal implant. Patient presented with persistent clinically significant macular edema in both eyes. Right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 mL with an interval of four weeks. After six weeks of follow–up, dexamethasone implant in the right eye showed normal macular thickness whereas persistent macular edema was found even after second intravitreal bevacizumab injection in the left eye.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.